Cardiff Oncology, Inc. Revenue From Contract With Customer Excluding Assessed Tax

• Cardiff Oncology, Inc. showed a decrease of -13.2% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
• This data is from Cardiff Oncology, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 6 years of available data (2020 to 2025), Cardiff Oncology, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 62.0%.
• Historical annual values: Fiscal year 2025: $593.0 thousand | Fiscal year 2024: $683.0 thousand | Fiscal year 2023: $488.0 thousand | Fiscal year 2022: $386.0 thousand | Fiscal year 2021: $359.0 thousand | Fiscal year 2020: $366.0 thousand.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026